174 related articles for article (PubMed ID: 16462494)
1. A phase I dose finding study of cisplatin, gemcitabine, and weekly docetaxel for patients with advanced transitional cell cancer.
Tinker A; Winquist E; Canil C; Moore M; Murray RN; Chi KN
Am J Clin Oncol; 2006 Feb; 29(1):3-7. PubMed ID: 16462494
[TBL] [Abstract][Full Text] [Related]
2. Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial.
Pectasides D; Glotsos J; Bountouroglou N; Kouloubinis A; Mitakidis N; Karvounis N; Ziras N; Athanassiou A
Ann Oncol; 2002 Feb; 13(2):243-50. PubMed ID: 11886001
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer.
Artz A; Stadler WM; Vogelzang NJ; Zimmerman T; Ryan C
Am J Clin Oncol; 2005 Apr; 28(2):109-13. PubMed ID: 15803001
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma.
Gitlitz BJ; Baker C; Chapman Y; Allen HJ; Bosserman LD; Patel R; Sanchez JD; Shapiro RM; Figlin RA
Cancer; 2003 Nov; 98(9):1863-9. PubMed ID: 14584068
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer.
Jang J; Kim HK; Cho BC; Lee KH; Yun HJ; Woo IS; Song HS; Ryoo HM; Kim CH; Sun DS; Shin JW
Cancer Chemother Pharmacol; 2017 May; 79(5):873-880. PubMed ID: 28341958
[TBL] [Abstract][Full Text] [Related]
6. Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery.
Abratt RP; Sandler A; Crinò L; Steward WP; Shepherd FA; Green MR; Nguyen B; Peters GJ
Semin Oncol; 1998 Aug; 25(4 Suppl 9):35-43. PubMed ID: 9728583
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium.
Hutson TE; Vukelja S; Atienza D; Awasthi S; Delaune R; Deutsch M; Dien PY; Gregory TF; Kolodziej MJ; Muscato JJ; Raju RN; Ruxer RL; Mull S; Ilegbodu D; Hood K; Nicol S; Berry W
Invest New Drugs; 2008 Apr; 26(2):151-8. PubMed ID: 18236006
[TBL] [Abstract][Full Text] [Related]
8. Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium.
Lorusso V; Crucitta E; Silvestris N; Rosati G; Manzione L; De Lena M; Palmeri S; Gebbia V; Mancarella S; Sobrero A; Pezzella G; Comella P; Mangiameli A; Muci D;
Oncol Rep; 2005 Feb; 13(2):283-7. PubMed ID: 15643512
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies.
Spiridonidis CH; Laufman LR; Jones J; Rhodes VA; Wallace K; Nicol S
J Clin Oncol; 1998 Dec; 16(12):3866-73. PubMed ID: 9850032
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer.
Bhargava P; Marshall JL; Fried K; Williams M; Lefebvre P; Dahut W; Hanfelt J; Gehan E; Figuera M; Hawkins MJ; Rizvi NA
Cancer Chemother Pharmacol; 2001 Aug; 48(2):95-103. PubMed ID: 11561784
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen.
Adamo V; Magno C; Spitaleri G; Garipoli C; Maisano C; Alafaci E; Adamo B; Rossello R; Scandurra G; Scimone A
Oncology; 2005; 69(5):391-8. PubMed ID: 16319510
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial.
Pectasides D; Visvikis A; Aspropotamitis A; Halikia A; Karvounis N; Dimitriadis M; Athanassiou A
Eur J Cancer; 2000 Jan; 36(1):74-9. PubMed ID: 10741298
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel and gemcitabine combination therapy in advanced transitional cell carcinoma of the urothelium: results of a phase II and pharmacologic study.
Dumez H; Martens M; Selleslach J; Guetens G; De Boeck G; Aerts R; De Bruijn EA; Maes RA; van Oosterom AT
Anticancer Drugs; 2007 Feb; 18(2):211-8. PubMed ID: 17159607
[TBL] [Abstract][Full Text] [Related]
14. Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial.
Schmid P; Krocker J; Schulz CO; Michniewicz K; Dieing A; Eggemann H; Heilmann V; Blohmer JU; Sezer O; Elling D; Possinger K
Anticancer Drugs; 2005 Jan; 16(1):21-9. PubMed ID: 15613900
[TBL] [Abstract][Full Text] [Related]
15. Palliative chemotherapy with gemcitabine, paclitaxel, and cisplatin as first-line treatment following gemcitabine monotherapy for patients with transitional cell carcinoma of the urothelium.
Ecke TH; Gerullis H; Bartel P; Koch S; Ruttloff J
Minerva Urol Nefrol; 2009 Mar; 61(1):1-8. PubMed ID: 19417721
[TBL] [Abstract][Full Text] [Related]
16. A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer.
Hussain SA; Stocken DD; Riley P; Palmer DH; Peake DR; Geh JI; Spooner D; James ND
Br J Cancer; 2004 Aug; 91(5):844-9. PubMed ID: 15292922
[TBL] [Abstract][Full Text] [Related]
17. Impact of Gemcitabine and Cisplatin with radiotherapy in locally advanced or metastatic transitional cell carcinoma of urinary bladder.
Mallick JA; Ali SA; Siddiqui N; Fareed A
J Pak Med Assoc; 2003 Nov; 53(11):547-52. PubMed ID: 14738263
[TBL] [Abstract][Full Text] [Related]
18. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.
Bellmunt J; Guillem V; Paz-Ares L; González-Larriba JL; Carles J; Batiste-Alentorn E; Sáenz A; López-Brea M; Font A; Nogué M; Bastús R; Climent MA; de la Cruz JJ; Albanell J; Banús JM; Gallardo E; Diaz-Rubio E; Cortés-Funes H; Baselga J
J Clin Oncol; 2000 Sep; 18(18):3247-55. PubMed ID: 10986057
[TBL] [Abstract][Full Text] [Related]
19. [The efficacy and toxicity of gemcitabine and cisplatin chemotherapy in advanced/metastatic bladder urothelial carcinoma].
Gunlusoy B; Arslan M; Vardar E; Degirmenci T; Kara C; Ceylan Y; Kozacıoğlu Z
Actas Urol Esp; 2012 Oct; 36(9):515-20. PubMed ID: 22819345
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine plus docetaxel as first-line biweekly therapy in locally advanced and/or metastatic urothelial carcinoma: a phase II study.
Neri B; Vannini L; Giordano C; Grifoni R; Pantaleo P; Baldazzi V; Crisci A; Lapini A; Raugei A; Carini M
Anticancer Drugs; 2007 Nov; 18(10):1207-11. PubMed ID: 17893522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
